Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population

Table 3 Treatment characteristics of eligible patients

	Total (n = 95)	Oral (n = 57)	Infusional (n = 38)	P value
Chemotherapy backbone (%)1
FOLFOX	26 (27.4)	0 (0)	26 (68.4)
CAPOX	43 (45.3)	43 (75.4)	0 (0)
FOLFIRI	12 (12.6)	0 (0)	12 (31.6)
CAPIRI	9 (9.5)	9 (15.8)	0 (0)
Capecitabine	5 (5.3)	5 (8.8)	0 (0)
Type of fluoropyrimidine (%)
Oral	57 (60.0)	57 (100)	0 (0)
Infusional	38 (40.0)	0 (0)	38 (100)
Chemotherapy partner (%)
Oxaliplatin	69 (76.7)	43 (75.4)	26 (68.4)	0.184
Irinotecan	21 (23.3)	9 (15.8)	12 (31.6)
Mean treatment duration
Oral/Infusional FP (wk)2	18.5	19.4	17.2	0.147
Any treatment modification (%)
Yes	75 (78.9)	43 (75.4)	32 (84.2)	0.441
Due to age	21 (22.1)	12 (21.1)	9 (23.7)
Due to adverse effects	54 (56.8)	31 (54.4)	23 (60.5)
Subsequent systemic therapy (%)
Yes	65 (68.4)	40 (70.2)	25 (65.8)	0.822
Metastasectomy of curative intent (%)
Yes	16 (16.8)	6 (10.5)	10 (26.3)	0.083

There was no statistically significant difference in the proportions of patients receiving treatment modification of the first-line treatment, metastasectomy of curative intent, subsequent systemic therapy, and the mean treatment durations in the two treatment groups.

¹The details of the regimen are shown in Table 1;

²FP refers to fluoropyrimidine.